UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTER ENDED ~~DECEMBER~~September 3130, ~~2013~~2014

Commission File No. 000-52771

PURAMED BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Minnesota		20-5510104
Nevada		20-5510104
(State or other jurisdiction of Incorporation or organization)		(IRS Employer ID Number)

1326 Schofield Avenue Schofield, WI		54476
(Address of principal executive offices)		(Zip Code)

(715) 359-6373

(Registrant’s telephone number)

Check whether the Issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES þ NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES þ NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule12b-2 of the Exchange Act. (Check one):

Large accelerated filer ~~oAccelerated~~ o Accelerated filer ~~oNon~~ o Non-accelerated filer ~~oSmaller~~ o Smaller reporting company þ

Indicate by checkmark whether registrant is a shell company. o

There were ~~316~~199,~~273~~821,~~077~~079 shares of Common Stock outstanding as of ~~February~~November 617, 2014.

TABLE OF CONTENTS

				Page
PART I – FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION				3
Item 1.	UNAUDITED CONDENSED FINANCIAL STATEMENTS		3
Item 1.	UNAUDITED CONDENSED FINANCIAL STATEMENTS			3
	Unaudited Condensed Balance Sheets		3
	Unaudited Condensed Balance Sheets			3
	Unaudited Condensed Statements of Operations		4
	Unaudited Condensed Statements of Operations			4
	Unaudited Condensed Statements of Cash Flows		5
	Unaudited Condensed Statements of Cash Flows			5
	Notes to Condensed Unaudited Financial Statements		6
	Notes to Condensed Unaudited Financial Statements			6
Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		12
Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS			10
Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		23
Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK			21
Item 4.	CONTROLS AND PROCEDURES		23
Item 4.	CONTROLS AND PROCEDURES			21
PART II – OTHER INFORMATION
PART II. OTHER INFORMATION				22
Item 1.	LEGAL PROCEEDINGS AND RISK FACTORS		24
Item 1.		LEGAL PROCEEDINGS AND RISK FACTORS		22
Item 1a.	RISK FACTORS		24
Item 1a.		RISK FACTORS		22
Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		24
Item 2.		UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		22
Item 3.	DEFAULTS UPON SENIOR SECURITIES		24
Item 3.		DEFAULTS UPON SENIOR SECURITIES		22
Item 4.	MINE SAFETY DISCLOSURES		24
Item 4.		MINE SAFETY DISCLOSURES		22
Item 5.	OTHER INFORMATION		24
Item 5.		OTHER INFORMATION		22
Item 6.	EXHIBITS		25
ITEM 6.		EXHIBITS		23

[2]

PART I – FINANCIAL INFORMATION

ITEM 1. UNAUDITED CONDENSED FINANCIAL STATEMENTS

PURAMED BIOSCIENCE, INC.

Unaudited Condensed Balance Sheets

	December 31,			June 30,
	September 30,			June 30,
	2013			2013
	2014			2014
	(unaudited)
ASSETS
Current Assets
Current Assets:
Cash	$	-28,120		$	4148,~~180~~576
Accounts Receivable		-600			~~25,119~~-
Inventory		298,~~317~~467			~~203~~1,~~906~~000
Prepaid Expenses		~~20,349~~-			5621,~~039~~500
Total Current Assets		4937,~~666~~187			~~326~~71,~~244~~076
Property and Equipment
Property and Equipment:
Computer Software		2,~~483~~638			2,~~483~~638
Computer Hardware		59,~~570~~070			59,~~338~~070
Equipment		2,136			2,136
Accumulated Depreciation		(68,~~233~~335	)		(57,~~090~~472	)
Net Property and Equipment		35,~~956~~509			46,~~867~~372
Other Assets
Other Assets:
PuraMed Bioscience Products, net of accumulated
Trademarks, net of amortization of $10,260 and $10,010, respectively		8,741			8,991
amortization of $322,420 and $298,418, respectively		13,612			37,614
Patents, net of amortization of $11,184 and $8,784, respectively		95,315			91,683
Trademarks, net of amortization of $3,592 and $2,754, respectively		14,511			13,383
Deferred Financing Fees		3,924			8,216
Patents, net of amortization of $5,856 and $2,928, respectively		89,363			89,511
Total Other Assets		107,980			108,890
Deferred Financing Fees		11,183			4,727
Total Assets	$	150,676		$	186,338
Total Other Assets		128,669			145,235
Total Assets	$	182,291		$	476,346
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Current Liabilities:
Accounts Payable	$	~~957~~850,~~403~~954		$	~~627~~791,~~427~~915
Accrued Wages - Officers		~~553~~469,~~570~~125			~~435~~440,~~326~~401
Accrued Expenses		~~199~~309,~~253~~043			~~120~~301,~~040~~675
Short-term Term Note		525,000			525,000
Short-term Convertible Notes, net of discount		~~528~~532,~~886~~715			~~454~~320,~~025~~574
Convertible Bond Payable, net of discount		598,733			598,733
Convertible Bond Payable		598,733			598,733
Derivative Liability - Warrants		~~1,363~~355			~~10,178~~355
Derivative Liability - Convertible Debt		~~882~~2,~~341~~380,028			~~400~~2,~~270~~345,961
Total Current Liabilities		45,~~246~~665,~~549~~953			35,~~170~~324,~~999~~614
Conditionally Redeemable Stock		75,000			75,000
Commitments and Contingencies
Stockholders' Deficit
Stockholders' Deficit:
Common Stock, $.001 par value, 1,000,000,000 shares
Series A Preferred Stock, $.000001 par value, 51 shares
authorized, 142,857,622 shares and 51,110,297 shares issued
authorized, issued and outstanding		-			-
and outstanding, respectively		142,858			51,110
Series B Preferred Stock, $.000001 par value, 5,000,000 and 0 shares
Additional Paid in Capital		5,680,179			5,528,469
authorized, 4,500,000 issued and outstanding, respectively		5			5
Accumulated Deficit		(9,962,295	)		(8,349,232	)
Common Stock, $.000001 par value, 4,000,000,000 shares
Total Stockholders' Deficit		(4,139,258	)		(2,769,653	)
authorized, 70,662,185 and 27,105,175 shares issued
Total Liabilities and Stockholders' Deficit	$	182,291		$	476,346
and outstanding, respectively		71			27
Additional Paid in Capital		8,882,451			8,436,847
Accumulated Deficit		(14,397,804	)		(13,575,155	)
Total Stockholders' Deficit		(5,515,277	)		(5,138,276	)
Total Liabilities and Stockholders' Deficit	$	150,676		$	186,338

See accompanying notes to ~~unaudited condensed~~ financial statements.

[3]

PURAMED BIOSCIENCE, INC.

Unaudited Condensed Statements of Operations

	Three Months Ended						~~Six Months Ended~~
	December 31, 2013			December 31, 2012			December 31, 2013			December 31, 2012
	September 30, 2014			September 30, 2013
Net Revenues	$	-3,636		$	-		$	-		$	~~27,534~~
Cost of Sales		~~386~~4,~~013~~932			1526,~~024~~603			~~412,616~~			~~28,067~~
Gross Loss		(~~386~~1,~~013~~296	)		(1526,~~024~~603	)		~~(412,616~~	)		~~(533~~	)
Operating Expenses
Selling, General and Administrative Expenses		5423,~~427~~774			5043,~~557~~226			~~97,653~~			~~106,108~~
Amortization and Depreciation Expense		143,~~472~~513			1214,~~975~~440			~~28,912~~			~~25,951~~
Professional Fees		5148,~~875~~897			~~110~~107,~~165~~930			~~159,805~~			~~270,494~~
Marketing and Advertising Expense		569,~~857~~770			6822,~~827~~990			~~79,847~~			~~316,338~~
Research and Development		-			56			-			14,656
Salaries		5,874			7,436
Salaries		6,996			7,040			14,432			14,300
Officer's Salaries		42,314			60,923
Officer's Salaries		60,923			90,462			121,846			167,820
Total Operating Expenses		134,142			256,945
Total Operating Expenses		245,550			340,082			502,495			915,667
Loss from Operations		(135,438	)		(283,548	)
Loss from Operations		(631,563	)		(355,106	)		(915,111	)		(916,200	)
Other Expense
Other Income/(Expense)
Interest Expense		(431,930	)		(125,999	)
Interest Expense		(170,174	)		(146,316	)		(296,173	)		(295,649	)
Loss on Derivative Liability		(255,281	)		(293,171	)
Gain (Loss) on Derivative Liability		(108,608	)		182,062			(401,779	)		111,825
Other Expense		(687,211	)		(419,170	)
Other Income/(Expense)		(278,782	)		35,746			(697,952	)		(183,824	)
Net Loss	$	(822,649	)	$	(702,718	)
Net Loss	$	(910,345	)	$	(319,360	)	$	(1,613,063	)	$	(1,100,024	)
Loss per Common Share - Basic
Loss per Common Share - Basic
and Diluted	$	(0.02	)	$	(0.51	)
and Diluted	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.04	)
Weighted Average Common Shares
Weighted Average Common Shares
Outstanding - Basic and Diluted		51,974,227			1,374,750
Outstanding - Basic and Diluted		75,623,864			27,552,057			65,306,934			26,219,462

See accompanying notes to ~~unaudited condensed~~ financial statements.

[4]

PURAMED BIOSCIENCE, INC.

Unaudited Condensed Statements of Cash Flows

	Six Months Ended
	Three Months Ended
	December 31, 2013			December 31, 2012
	September 30, 2014			September 30, 2013
Cash flows from operating activities
Cash flows from operating activities:
Net loss	$	(1822,~~613,063~~649	)	$	(1702,~~100,024~~718	)
Changes in non cash working capital items:
Depreciation		~~1,143~~863			~~1,143~~572
Amortization		272,~~769~~650			2413,~~810~~868
Amortization of deferred financing fees		107,~~410~~292			-3,581
Accretion on discount on convertible bond		-			50,490
Accretion on discount on convertible notes		374,767			76,701
Accretion on discount on convertible notes		181,649			227,913
Loss on derivative liability		255,281			293,171
Day-one loss on derivative liability		95,394			145,716
Changes in operating assets and liabilities:
Loss (gain) on derivative liability		306,385			(257,541	)
Accounts receivable		(600	)		(15,638	)
Changes in Operating assets and liabilities:
Inventory		(7,467	)		4,443
Accounts receivable		25,119			3,370
Prepaid expenses		21,500			32,006
Inventory		174,589			(33,706	)
Accounts payable		59,039			77,377
Prepaid expenses		35,690			(102,601	)
Accrued wages - officers		28,724			52,661
Accounts payable		329,976			84,106
Accrued expenses		37,176			33,748
Accrued wages - officers		118,244			118,720
Net cash used for operating activities		(43,424	)		(130,228	)
Accrued expenses		79,213			130,189
Cash flows from investing activities:
Net cash used for operating activities		(227,482	)		(707,415	)
Patent acquisition costs		(6,032	)		(2,779	)
Cash flows from investing activities
Property and equipment acquisition costs		-			(232	)
Patent acquisition costs		-			(5,490	)
Net cash used for investing activities		(6,032	)		(3,011	)
Property and equipment acquisition costs		(232	)		-
Cash flows from financing activities:
Trademark acquisition costs		(1,966	)		-
Proceeds from notes		29,000			92,830
Net cash used for investing activities		(2,198	)		(5,490	)
Net cash provided by financing activities		29,000			92,830
Cash flows from financing activities
Net decrease in cash		(20,456	)		(40,409	)
Proceeds from notes		188,500			655,000
Cash at beginning of the period		48,576			41,180
Proceeds from sale of stock and warrants,
Cash at end of the period	$	28,120		$	771
net of issuance costs		-			61,350
Net cash provided by financing activities		188,500			716,350
Change in cash		(41,180	)		3,445
Cash at beginning of the period		41,180			562
Cash at end of the period	$	-		$	4,007
Supplemental disclosures of noncash investing and financing activities and other cash flow information:
Short-term debt and accrued interest converted to
Short-term convertible notes and accrued liabilities converted to common stock	$	192,060		$	50,730
common stock	$	121,417		$	162,240
Retirement of derivative liability - convertible debt		253,588			17,357
Retirement of derivative liability - convertible debt		121,523			213,214
Issuance of derivative liability - convertible debt		50,594			151,592
Issuance of derivative liability - convertible debt		288,394			205,000
Interest paid with cash		-			14,263
Issuance of common stock for debt discount		-			115,000
Interest paid with cash		14,263			50,717

See accompanying notes to ~~unaudited condensed~~ financial statements.

[5]

PURAMED BIOSCIENCE, INC.

Notes to Condensed Unaudited Financial Statements

A. Basis of Presentation

The condensed balance ~~sheets~~sheet as of ~~December~~September 3130, ~~2013~~2014, the condensed statements of operations for the three ~~and six~~ month periods ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013 and the condensed statements of cash flows for the ~~six~~three month periods ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013 have been prepared by PuraMed BioScience, Inc. (the "Company") without audit. In the opinion of management, all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position as of ~~December~~September 3130, ~~2013~~2014 and the results of operations and cash flows for the three ~~and six~~ month periods ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013 presented herein have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with the United States generally accepted accounting principles have been condensed or omitted. These financial statements should be read in conjunction with the Company's financial statements and notes thereto for the fiscal year ended June 30, ~~2013~~2014 included in the Annual Report on Form 10-K of the Company filed with the SEC on October 1514, ~~2013~~2014.

B. Going Concern

As of ~~December~~September 3130, ~~2013~~2014, the Company had negative working capital and minimal funds needed to accomplish its planned business strategy or support its projected expenses. The Company plans to obtain the needed working capital primarily through debt issuances and sales of its common stock, which there is no assurance it will be able to accomplish. If the Company cannot obtain substantial working capital through debt issuances, common stock sales or other sources (if any), it most likely will be forced to curtail its planned business operations. If the Company is unable to obtain additional financing, its ability to continue as a going concern is doubtful.

C. Accounting Policies

Loss per common share – Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per common share assumes the exercise of stock options and warrants using the treasury stock method, if dilutive. Potentially dilutive shares of 622,191,101 and 2,157,821, for the three months ended September 30, 2014, and 2013, respectively were not included in the calculation of diluted shares, as ~~their~~the effect would have been antidilutive.

~~Product~~Trademark Amortization – PuraMed® BioScience ~~products~~trademarks consist ~~primarily~~ of the ~~cost~~legal ofcosts ~~trade~~associated ~~secrets~~with registering its LipiGesic®, ~~formulas~~MigraPure, ~~scientific~~ and ~~manufacturing~~PuraMed® ~~know-how,~~BioScience ~~trade~~trademarks. ~~names,~~As ~~marketing~~these ~~material~~trademarks ~~and~~have ~~other~~been ~~intellectual~~approved, ~~property~~they ~~and~~ are being amortized on a straight-line basis over an estimated useful life of ~~seven~~ten years.

Trademark Amortization – PuraMed® BioScience trademarks consist of the legal costs associated with registering our LipiGesic® and PuraMed® BioScience trademarks. As these trademarks have been approved, they are being amortized on a straight-line basis over an estimated useful life of ten years.

Fair Value Measurements

Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

[6]

PURAMED BIOSCIENCE, INC.

Notes to Condensed Unaudited Financial Statements

C. Accounting Policies (continued)

Level 1 Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.

Level 2 Other inputs that are observable directly or indirectly, such as quoted prices for similar assets and liabilities or market corroborated inputs.

Level 3 Unobservable inputs that are used when little or no market data is available, which require the Company to develop its own assumptions about how market participants would value the assets or liabilities.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosure each quarter. Assets and liabilities measured at fair value on a recurring basis as of ~~December~~September 3130, ~~2013~~2014 and June 30, ~~2013~~2014 are summarized as follows:

Fair Value as of December 31, 2013

Fair Value as of September 30, 2014

Level 1

Level 2

Level 3

Total

Liabilities

Derivative Liability - Warrants

~~1,363~~355

Derivative Liability – Convertible Debt

~~882~~2,~~341~~380,028

Total

~~883~~2,~~704~~380,383

Fair Value as of June 30, 2013

Fair Value as of June 30, 2014

Level 1

Level 2

Level 3

Total

Liabilities

Derivative Liability - Warrants

~~10,178~~355

Derivative Liability – Convertible Debt

~~400~~2,~~270~~345,961

Total

~~410~~2,~~448~~346,316

~~The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value on a recurring basis during the six months ended December 31, 2013:~~[7]

	Fair Value Measurements Using Significant
	Unobservable Inputs (Level 3)
				Derivative
	Derivative			Liability -
	Liability -			Convertible
	Warrants			Debt			Total
Beginning balance, July 1, 2013	$	10,178		$	400,270		$	410,448
Issuance		-			193,000			193,000
Retirements		-			(121,523	)		(121,523	)
(Gain) loss on derivative liability		(8,815	)		410,594			401,779
Ending balance, December 31, 2013	$	1,363		$	882,341		$	883,704

The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value on a recurring basis during the three months ended September 30, 2014:

A binomial option-pricing model was used to value the derivative liability with the following inputs:

	Fair Value Measurements Using Significant
	Unobservable Inputs (Level 3)
			Derivative
	Derivative		Liability -
	Liability -		Convertible
	Warrants		Debt			Total
Beginning balance, July 1, 2014	$	355	$	2,345,961		$	2,346,316
Issuance		-		32,000			32,000
Retirements		-		(253,214	)		(253,214	)
Loss on derivative liability		-		255,281			255,281
Ending balance, September 30, 2014	$	355	$	2,380,028		$	2,380,383

●	Stock Price – The Stock Price was based on the closing price of the Company’s common stock on the valuation date. The valuation date can either be the date of issuance of the convertible debt note or the last day of a reporting period (the Valuation Date). Stock prices on the Valuation Dates ranged from $0.002 to $0.02.
●	Variable Conversion Price – The variable conversion price was based on 50% to 60% of the average of the three lowest stock bid prices out of the last 10 trading days prior to the Valuation Date.

[8]

●	Time to Maturity – The time to maturity was determined based on the length of time between the Valuation Date and the maturity of the debt.
●	Risk Free Rate – The risk free rate was based on the US treasury note rate as of the Valuation Dates with term commensurate with the remaining term of the debt. The risk free rate used was .09%.

● Volatility – The volatility was based on the historical volatility of the Company, using a time period to calculate volatility commensurate with the Time to Maturity.

PURAMED BIOSCIENCE, INC.

Notes to Condensed Unaudited Financial Statements

A binomial option-pricing model was used to value the derivative liability with the following inputs:

●	Stock Price – The Stock Price was based on the closing price of the Company’s common stock on the valuation date. The valuation date can either be the date of issuance of the convertible debt note or the last day of a reporting period (the Valuation Date). Stock prices on the Valuation Dates ranged from $0.004 to $11.80.
●	Exercise Price – The exercise price, or conversion price was based on the terms of the associated agreement, which for the convertible notes is usually based on a percentage of the average of the three lowest stock bid prices out of the last 10 trading days prior to the Valuation Date.

●	Time to Maturity – The time to maturity was determined based on the length of time between the Valuation Date and the maturity of the associated instruments.
●	Risk Free Rate – The risk free rate was based on the US treasury note rate as of the Valuation Dates with term commensurate with the remaining term of the debt. The risk free rate ranged between .09% and 1.60 %.

●	Volatility – The volatility was based on the historical volatility of the Company, using a time period to calculate volatility commensurate with the Time to Maturity. Volatilities used ranged between 278% and 369%.

Recently Enacted Accounting Standards

InOn ~~July~~May ~~2013~~28, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards ~~(ASC)~~ Update No. ~~2013~~2014-1109 –(ASU ~~Income Taxes. In April 2013~~2014-09), ~~FASB~~Revenue ~~issued~~from ~~ASC~~Contracts ~~Update~~with NoCustomers. ~~2013~~ASU 2014-0709 –will ~~Presentation~~require ofthat ~~Financial~~companies ~~Statements. In~~recognize ~~February~~revenue ~~2013,~~based ~~FASB~~on ~~issued~~the ~~ASC~~value ~~2013-04,~~of ~~Liabilities. In~~transferred ~~January~~goods ~~2013,~~or ~~FASB~~services ~~issued~~as ~~ASC~~they ~~Update~~occur Noin the contract. ~~2013-01~~The –ASU ~~Clarifying~~also ~~the~~will ~~Scope~~require ofadditional ~~Disclosures~~disclosure about ~~Offsetting~~the ~~Assets~~nature, amount, timing and ~~Liabilities. In~~uncertainty ~~October~~of ~~2012,~~revenue ~~FASB~~and ~~issued~~cash ~~ASC~~flows ~~Update~~arising ~~No.~~from ~~2012-04~~customer –contracts, ~~Technical~~ASU ~~Corrections~~2014-09 ~~and~~is ~~Improvements. In~~effective ~~August~~for ~~2012,~~reporting ~~FASB~~periods ~~issued~~beginning ~~ASC~~after ~~Update~~December ~~No.~~15, ~~2012-03~~2016, –and ~~Technical~~early ~~Amendments~~adoption ~~and~~is ~~Corrections~~not topermitted. ~~SEC~~Management ~~Sections: Amendments~~is tocurrently ~~SEC~~evaluating ~~Paragraphs~~the ~~Pursuant~~impact, toif ~~SEC~~any, ~~Staff~~on ~~Accounting~~adopting ~~Bulletin~~ASU ~~No.~~2014-09 ~~114,~~on ~~Technical~~our ~~Amendments~~results ~~Pursuant~~of tooperations ~~SEC~~or ~~Release~~financial Nocondition. The ~~33-9250,~~Company has considered this and ~~Corrections~~other ~~Related~~recent toaccounting ~~FASB~~pronouncements ~~Accounting~~of ~~Standards~~which ~~Update~~the ~~2010-22. In~~Company ~~July~~is ~~2012~~aware, ~~FASB~~and ~~issued~~the ~~Update~~Company ~~No.~~believes ~~2012-02~~their –adoption ~~Intangibles~~has –not ~~Goodwill~~had, and ~~Other~~will ~~(Topic~~not ~~350)~~have, ~~testing~~any ~~Indefinite-Lived~~material ~~Intangible~~impact ~~Assets~~on ~~for~~our ~~Impairment~~financial position or results of operations.

The Company has considered these and other recent accounting pronouncements of which the Company is aware, and the Company believes their adoption has not had, and will not have, any material impact on our financial position or results of operations.[9]

PURAMED BIOSCIENCE, INC.

Notes to Condensed Unaudited Financial Statements

D. Inventory

Inventory consists of raw materials and finished goods. Raw materials are the components, including boxes, inserts, liquid medicine and packaging materials that have not been combined into the final product, ready for sale. Finished goods are the final product, available for sale. The raw materials inventory ~~will~~is expected to be assembled and placed in finished goods inventory when that amount is significantly reduced. Due to the lack of degradation of the material, no adjustment for obsolescence is necessary. Inventory consisted of the following as of ~~December~~September 3130, ~~2013~~2014 and June 30, ~~2013~~2014:

	December 31, 2013			June 30, 2013
	September 20, 2014			June 30, 2014
Raw Materials	$	297,~~317~~467		$	~~29,345~~-
Finished Goods		~~166~~1,~~416~~000			~~174~~1,~~561~~000
Reserve for inventory obsolescence		(166,416	)		-
Total Inventory	$	8,467		$	1,000
Total Inventory	$	29,317		$	203,906

E. Notes Payable Transactions

The Company has issued various 8% to 12% secured convertible notes (the Convertible Notes). The Company has bifurcated the convertible debt agreements according to the guidance provided by ASC 815-15-25. The principal and accrued interest for these notes is payable nine to twelve months after issuance, or such earlier date as defined in the agreement. The notes are convertible by the holder at any time after the issue date and by the Company at any time after issue with conversion periods as defined in the agreement. The notes are convertible into shares of the Company’s common stock at a price of 50% to 60% of the average of the three lowest closing bid prices of the stock during the defined trading day period ending one day prior to the date of conversion. The holders are not entitled to convert any portion of the Convertible Notes to the extent that the shares to be issued in connection therewith would cause the holder’s beneficial ownership of the Company’s common stock to exceed 4.99% of the outstanding shares of the Company’s common stock. Because of the operation of the floating conversion price and the holder’s ability to convert as described above, the Company is unable to determine at any time that number of shares into which the Convertible Notes ~~are~~may be convertible. ~~As of December 31, 2013, the balance of the Convertible Notes was $705,835, net of discount of $176,949.~~

The Convertible Notes contain customary representations and warranties, customary affirmative and negative covenants, customary anti-dilution provisions, and customary events of default that accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the Convertible Notes. A default on the Convertible Notes could lead to certain penalties, including an obligation to (a) pay all of the following, plus an additional 50% of (i) default interest, (ii) other monetary penalties, and (iii) the outstanding balance on the Convertible Notes. As of September 30, 2014, the balance of the Convertible Notes is $532,715, net of discount of $463,253.

The holders are entitled to have all shares issued upon conversion listed upon each national securities exchange or other automated quotation system, if any, upon which shares of the Company’s common stock are then listed.

The Company is required to carry the embedded derivatives on its balance sheet at fair value and account for any unrealized change in fair value as a component in its results of operations. The Company valued the embedded derivatives using a binomial option-pricing model.

8[10]

PURAMED BIOSCIENCE, INC.

Notes to Condensed Unaudited Financial Statements

E. Notes Payable Transactions (continued)

The Company entered into a convertible note in the amount of $500,000 with an individual who is now a Director of the Company on November 13, 2009. The note expired on November 12, 2012, and a new note in the amount of $598,733 was entered into on January 31, 2013, with an interest rate of 8% and the right to pay off the note in whole or in part at any time. The new note is the balance of the former note plus expenses of $98,233, paid by the Board Member on behalf of the Company. The Company has not begun servicing this note.

During 2013, the Company entered into a material definitive agreement with TCA Global Credit Master Fund, LP, a Cayman Islands limited partnership (TCA), with a promissory note in the amount of $350,000. Interest was is ~~due~~ and payable each month at a rate of 12%. The note has a cross default clause and has a continuing, first priority security until such time as the note is repaid. This note is convertible only upon default. No derivative has been recorded because the value is nominal. As further consideration for TCA entering into and structuring the promissory note, the Company paid TCA a fee of $115,000, with consideration of 479,167 shares of common shares of the Company, which ~~was~~is recorded as a debt discount, and amortized over the initial term of the debt of one year.

In June 2013, TCA restructured its debt agreement with the Company, which constituted a troubled debt restructuring, with the term of the debt extended through January 1, 2014. Subsequent to December 31, 2013 the Company has been in negotiations with the Lender to further restructure the debt agreement. Presently final terms of the loan restructure have not been completed. The principal balance of the note was increased to $368,757 (which included $14,000 of interest due to TCA) as a result of this debt restructuring. This balance iswas included with short-term convertible notes. Losses incurred as a result of this restructuring totaled $94,132, which consisted of the payment of $75,000 of common stock to TCA, the write-off of a remaining debt discount of $14,375 and an increase in the balance due to TCA of $4,757. The common stock issued to TCA is redeemable by the Company if TCA does not realize net proceeds of at least $75,000 from the shares within a twelve month period following receipt of the shares; accordingly, it has been classified outside of permanent equity. The asconditionally ofredeemable ~~December~~common 31stock totaling $190,000 ~~2013~~was ~~and~~reclassified ~~June~~to ~~30,~~convertible ~~2013~~notes during 2014.

InOn April ~~2013~~24, ~~two~~2014, ~~notes~~the ~~were~~Company ~~signed~~entered into a Master Exchange Agreement (the “Exchange Agreement”), with ~~Robert~~an ~~Libauer~~Institutional Investor (the “Institutional Investor”) for athe ~~total~~note initially issued by the Company to TCA, under which obligations of $~~525~~579,~~000~~109 were owed as of such date. Pursuant to the Exchange Agreement and subject to its terms and conditions, ~~which~~the ~~are~~Institutional ~~due~~Investor onmay, ~~April~~from 1time to time, ~~2014~~at the Institutional Investor’s sole option, ~~with~~exchange 8%obligations ~~interest~~under ~~compounded~~the ~~annually~~note, in whole or in part, for shares of the Company’s common stock. ~~These~~The ~~notes~~number ~~are~~of ~~secured~~common stock shares issuable to the Institutional Investor upon exchange of the obligation shall be determined by adividing ~~second~~the ~~position~~applicable “Exchange Amount” (as defined in ~~all~~the Agreement) by the ~~Company’s~~“Exchange ~~assets~~Price” (as defined in the Agreement). Since the closing date, the Institutional Investor has exchanged approximately $329,000 of the outstanding obligations under the note for common stock.

~~During~~In ~~the~~April ~~three months ended December 31,~~ 2013, ~~the~~two ~~Company~~notes ~~has~~were ~~issued~~signed ~~various~~with ~~secured~~an ~~convertible~~individual ~~notes~~for ~~totaling~~a total of $96525,000, ~~with~~which ~~four~~were ~~different~~due ~~organizations~~on ~~(Asher,~~April ~~JMJ~~1, ~~Tonaquint~~2014, ~~Brighton~~with ~~Capital)~~8% interest compounded annually. ~~The~~These ~~interest~~notes ~~rates~~are onsecured ~~these~~by ~~convertible~~a ~~notes~~second ~~vary~~position ~~from~~in 8%all tothe ~~22%~~Company’s assets. The Company has not begun servicing these notes.

F. Stockholders’ Equity (Deficit)

~~During~~On ~~the~~October ~~six months ended December 31~~7, ~~2013~~2014, the Company ~~issued~~effected a ~~total~~1-for-40 reverse split of ~~69,119,989~~ its common ~~shares~~stock. The innumber ~~payment~~ of ~~principal~~authorized ~~and~~shares ~~interest~~of ~~due~~common onstock ~~convertible~~was ~~notes~~also ~~totaling~~increased ~~$126~~to 4,~~820~~000,000,000. The ~~shares~~Company ~~were~~also ~~valued~~amended atits articles of incorporation, changing the par value of its common stock from $0.~~0007~~001 to $0.~~028 per share~~000001.

~~During the six months ended December 31, 2013, 22,627,336 common shares were issued in connection with the cashless exercise of warrants.~~[11]

PURAMED BIOSCIENCE, INC.

Notes to Condensed Unaudited Financial Statements

F. Stockholders’ Equity (Deficit) (continued)

All share and per share information in the accompanying financial statements have been restated retroactively to reflect the reverse stock split and change in par value.

During the three months ended September 30, 2014, the Company issued a total of 31,968,565 common shares in payment of accrued expenses, and of principal and interest due on convertible notes totaling $192,060.

During the three months ended September 30, 2014, 11,588,445 common shares were issued in connection with the cashless exercise of warrants.

G. Subsequent Events

Subsequent to ~~December~~September 3130, ~~2013~~2014, the Company issued convertible notes payable totaling $~~105~~75,500, due with interest ranging from 8% to 10% with maturity dates ranging from being due on demand to ~~February~~October, 37, 2015.

Subsequent to ~~December~~September 3130, ~~2013~~2014, ~~the~~notes ~~Company~~payable ~~issued~~and aaccrued ~~total~~interest of 86$69,~~791,345~~094 ~~common~~were ~~shares~~converted ininto ~~payment~~96,718,720 shares of ~~principal~~common ~~and interest due on convertible notes totaling $76~~stock. Also,~~470~~ ~~($71~~32,~~910~~439,735 ~~Principal~~shares ~~and~~of ~~$4,560~~common ~~Interest). The~~stock ~~shares~~ were ~~valued~~issued atpursuant ~~$0.00073~~ to $0the exercise of warrants.~~001.~~

Subsequent to December 31, 2013, 71,867,403 common shares were issued in connection with the cashless exercise of warrants.

Subsequent to December 31, 2013, the Company issued a total of 31,400,000 common shares in payment of principal and interest due on a convertible note totaling $23,700. The shares were valued at $0.000720 to $0.000780.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of ~~our~~the Company’s financial condition and plan of operations should be read and considered along with ~~our~~its condensed financial statements and related notes included in this Quarterly Report on Form 10-Q. Various statements have been made in this Quarterly Report on Form 10-Q that may constitute “forward-looking statements.” Forward-looking statements may also be made in the Company’s other reports filed with or furnished to the SEC and in other documents. In addition, from time to time, the Company, through its management, may make oral forward-looking statements. Forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from such statements. The words “believe,” “expect,” “anticipate,” “optimistic,” “intend,” “plan,” “aim,” “will,” “may,” “should,” “could,” “would,” “likely” and similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Background

PuraMed® BioScience®, Inc. (“PuraMed”, “PMBS” or the “Company”) was incorporated in Minnesota on May 9, 2006, as a wholly-owned subsidiary of Wind Energy America, Inc. (formerly “Dotronix, Inc.”) for the purpose of engaging in the business of developing and marketing non-prescription, over-the-counter healthcare products to remedy various ailments.

In late 2006, PuraMed’s former parent company decided to spin off its PuraMed subsidiary and related healthcare products business. Accordingly, on April 12, 2007, Wind Energy America, Inc. affected a spin-off of PuraMed to shareholders of Wind Energy America, Inc. on a pro rata dividend basis of one common share of PuraMed for each five common shares of Wind Energy America, Inc. Since April 12, 2007, the effective date of the spin-off, PuraMed and Wind Energy America, Inc. have operated separately, with ~~their~~the respective managements, businesses, assets, and capital structures being completely independent from each other.

[12]

Detailed information regarding this spin-off of PuraMed from Wind Energy America, Inc. (formerly Dotronix, Inc.) is contained in a Current Report on Form 8-K and exhibit thereto which were filed with the US Securities and Exchange Commission (the “SEC”) on April 10, 2007, and can be readily accessed at the SEC website www.sec.gov or the Company’s corporate website at http://www.puramedbioscience.com/sec-filings/.

On October 7, 2014, the Financial Industry Regulatory Authority (FINRA) effected in the marketplace (i) the change in the Company’s domicile from Minnesota to Nevada and (ii) a 1-for-40 reverse stock split.

Overview of Business

The Company is engaged in the business of developing and marketing a line of non-prescription medicinal or healthcare products to be marketed through various ~~retail~~independent ~~channels under the LipiGesic® brand~~ and ~~trademark~~retail channels. InThe anCompany ~~effort~~plans toon ~~add~~re-launching ~~continuity~~its toflagship ~~all~~product, ofLipiGesic ~~PuraMed’s~~® ~~products,~~under the ~~Company~~MigraPure ~~trademarked~~® ~~the~~ brand ~~name~~and ~~LipiGesic®~~trademark. The Company has recently completed ~~all~~the product development and design packaging for ~~our~~the ~~initial~~product ~~three~~and ~~products,~~has ~~LipiGesic®~~created Mother ~~(Migraine),~~intellectual ~~LipiGesic®~~assets Hto ~~(Tension~~promote ~~Headache)~~a ~~and~~successful ~~LipiGesic® PM (Insomnia)~~re-launch.

~~The~~In ~~Company~~addition ~~entered~~to ~~the~~MigraPure, ~~over-the-counter~~PuraMed ~~(OTC)~~BioScience ~~healthcare~~has ~~products~~created ~~marketplace~~an inenhanced ~~December~~formulation ~~2009, by employing “direct-to-consumer” marketing~~ for ~~our~~the ~~migraine~~relief ~~remedy~~of ~~via~~seizure-related ~~television~~headaches, ~~commercials~~which ~~and~~could ~~print~~become ~~articles. The~~part ~~Company~~of isthe ~~currently~~PuraMed ~~undergoing~~product ~~substantial activities to gain broad retail distribution through mainstream drug store chains, mass merchandisers, and food chains~~line.

The Company ~~has~~entered ~~maintained~~the aOver-The-Counter ~~retail~~(OTC) ~~presence~~healthcare inproducts ~~one~~marketplace ofin ~~the~~December ~~top~~2009, ~~national~~by ~~chain~~employing ~~drug~~“direct ~~stores,~~to ~~CVS,~~consumer” ~~and~~marketing ~~also~~for ~~had~~the aCompany’s ~~presence~~migraine ~~in Walgreens~~remedy. The Company is ~~also~~currently inundergoing ~~negotiations~~concerted ~~with~~efforts ~~several additional large retailers~~ to ~~stock~~re-enter ~~our~~the ~~LipiGesic®~~food M,and ~~migraine~~drug ~~product~~mass marketplace.

~~PuraMed~~The ~~executes~~Company ~~marketing campaigns that utilize clinical trial results to overcome consumer and retailer skepticism and to provide third-party validation of LipiGesic M’s efficacy. PuraMed~~ is ~~nearing~~also ~~the~~investigating ~~completion~~several ofstrategic aalliances ~~second~~that ~~clinical~~could ~~study~~enable ~~measuring~~ the ~~efficacy of LipiGesic M’s feverfew, ginger and olive oil formulation in pediatric and adolescent populations. The~~ Company isto ~~currently~~co-market ~~developing a social marketing campaign, medical community detailing~~ and ~~sampling~~build ~~strategy,~~market ~~and~~share ~~is researching the implementation~~ of acomplementary ~~continuing medical education (CME) program for doctors and pharmacists~~products.

10MigraPure® Advanced Migraine Relief (Clinically tested as LipiGesic® M)

~~The~~MigraPure’s ~~Company~~patented ~~continues~~feverfew ~~to develop~~ and ~~grow~~ginger ~~its~~gel ~~intellectual~~provides ~~property~~relief ~~and~~for ~~product~~acute ~~portfolio,~~migraine ~~which~~and ismigraine-like ~~expected~~headaches toincluding ~~substantially~~sinus ~~enhance~~and ~~shareholder~~hangover ~~value~~headaches. ~~Our~~PuraMed ~~scientific~~believes ~~team~~that ~~has~~the ~~gained~~specific ~~significant~~formulation ~~and~~of ~~exciting~~these ~~evidence~~active ~~from~~ingredients ~~our~~is ~~initial~~unique ~~research~~ and ~~management,~~proprietary. ~~which~~Clinical wetrial ~~expect~~data ~~will~~and ~~assist~~anecdotal usevidence inshows the ~~development~~sublingual offormulation aprovides ~~new~~relief ~~generation~~from ofthese ~~botanically~~severe ~~derived~~migraine ~~anti-inflammatory~~headaches ~~and~~within ~~pain management products with broad applications~~minutes.

~~LipiGesic®~~The MCompany hopes to capture a material segment of the migraine headache remedy market as a natural alternative to prescription and OTC migraine medications that may be less effective and induce severe and unpleasant side effects. The Company believes that Americans spend in excess of $6 billion annually on headache pain relievers, and that over half of sufferers of migraine headaches rely exclusively on non-prescription medications.

~~LipiGesic®~~The MCompany ~~provides~~believes ~~acute~~that ~~relief~~at ~~from~~least ~~migraine~~50 ~~pain~~million ~~and~~Americans ~~associated~~suffer ~~symptoms~~from ~~with~~chronic amigraine ~~formulation~~headaches ~~that~~with ~~contains~~over ~~the~~20 ~~herbs~~million ~~feverfew~~of ~~and~~them ~~ginger~~having as“severe” ~~principal~~migraine ~~ingredients~~conditions. Therefore ~~PuraMed~~migraine ~~BioScience~~headaches ~~holds~~constitute a USsevere ~~patent~~and ondisabling ~~the~~condition ~~LipiGesic~~for Mmillions ~~formulation,~~of ~~which~~people. The ~~has~~Company ~~been~~further ~~clinically~~believes ~~tested~~that ~~and~~the ~~has~~economic ~~been~~burden ~~found~~alone to ~~provide~~the ~~relief~~US ineconomy ~~64 percent of migraine occurrences. The formulation~~ is ~~unique~~in ~~and~~excess ~~often~~of ~~provides~~$50 ~~relief~~billion ~~from severe headache pain and associated symptoms in minutes~~annually.

~~LipiGesic®~~MigraPureis M is ~~effective,~~ available as a non-prescription remedy, provides a side effect profile similar to placebo, and ishas a significantly lower in cost compared to more expensive prescription migraine drugs.

InFuture light of the current Food and Drug Administration warnings regarding acetaminophen, ibuprofen, and naproxen sodium, along with the recently published American Headache Society guidelines that recommend restricting the frequency of use of both prescription and non-prescription headache treatments, PuraMed ~~believes~~BioScience® ~~that the adoption of LipiGesic M by the consumer and healthcare providers as a viable remedy will allow the product to capture a significant segment of the migraine headache remedy market.~~Products

WeThe ~~believe~~Company ~~that~~intends atto ~~least~~complete 50development ~~million Americans suffer from chronic migraine headaches with over 20 million~~ of ~~them~~additional ~~having~~non-prescription ~~“severe”~~hemp-based ~~migraine conditions~~products. WeThe ~~believe~~Company ~~that~~intends ~~Americans~~to ~~spend~~launch inthese ~~excess~~commercially ofover $6the ~~billion~~next ~~annually~~couple onyears ~~headache~~after ~~pain~~establishing ~~relievers,~~a ~~and~~solid ~~that~~market ~~over~~for ~~half~~MigraPure, ofthe ~~sufferers~~Company’s offlagship migraine ~~headaches rely exclusively on non-prescription medications~~formulation. WeAreas ~~further~~to ~~believe~~be ~~that~~addressed ~~the~~include ~~economic~~general ~~burden~~pain, ~~alone~~anxiety to/ ~~the~~depression US(post-traumatic ~~economy~~stress isdisorder) inand ~~excess~~other ofinflammatory ~~$50~~disease ~~billion annually~~states.

~~Therefore, we believe that migraine headaches constitute a severe and disabling condition for millions of people in America ... and worldwide.~~[13]

LipiGesic® H

LipiGesic® H provides relief for tension-type headaches which affect up to 90 percent of Americans at some point in their lives. LipiGesic® H is a unique sublingually delivered formulation utilizing acetylsalicylic acid and St. John’s Wort.

The combination of these two ingredients not only provides pain relief, but provides also relief from the anxiety that often exacerbates that pain. Current non-prescription tension headache pills often take up to an hour to begin working, and they often exhibit unwanted and dangerous side effects including stomach damage, liver damage, and rebound headaches. Prescription formulations often list even more dangerous side effects and are significantly more expensive.

Due to the use of sublingual delivery, the LipiGesic® H formulation can provide a safer, faster-acting alternative, while also dramatically reducing the potential for harmful side effects. LipiGesic® H will offer the hundreds of millions of Americans who suffer from tension-type headaches relief that is superior while also lowering their cost and risks of harmful side effects.

LipiGesic® PM

LipiGesic® PM is a new class of non-prescription sleep aid without any known side effects, which contains a proprietary blend of natural ingredients including Valerian, St. John’s Wort, and Chamomile. We believe that the proprietary blend of these ingredients provides an effective remedy for insomnia and other sleep disorders. The non-prescription sleep-aid market features products based on antihistamines, which are designed to treat allergies.

Accordingly, the LipiGesic® PM product provides a wide-open market opportunity for an effective, natural alternative to prescription medications, which are somewhat addictive and often cause withdrawal symptoms and other side effects. We plan to price LipiGesic® PM as a premium sleep aid product, which will provide us with a projected gross margin of approximately 80 percent. This large margin should leave us substantial room for ample introductory promotion, product allowances, and other incentives conducive to achieve rapid market penetration.

Similar to the migraine remedy market, the market for sleep-aid products represents a sizable segment of the overall healthcare products marketplace. We believe that over half of all adults in the US suffer from sleep disorders and that many of them experience persistent insomnia. The National Center on Sleep Disorders has reported that there are as many as 70 million problem sleepers in the U.S., with many of them suffering from chronic sleep disorders. We believe that insomnia is second only to pain as a healthcare complaint.

Future LipiGesic® Products

We have completed development of additional non-prescription products in the LipiGesic line, which we intend to launch after establishing a solid market for our initial products.

Sublingual Delivery System

~~LipiGesic®~~MigraPure MAdvanced (Migraine), ~~LipiGesic®~~Relief His ~~(Tension~~a ~~Headache), and LipiGesic® PM (Insomnia) are~~ non-prescription, liquid-gel ~~medications~~medication that ~~will~~absorbs ~~be absorbed “~~under-the- tongue”. This method of delivery is known as “sublingual.” ~~The~~This ~~use~~form of ~~sublingual~~ delivery ~~provides~~allows ~~fast~~the ~~relief~~active ~~for~~ingredients ~~whatever~~to ~~ailment~~reach orthe ~~condition~~bloodstream ~~that~~without isa ~~being~~substantial ~~treated~~degradation of efficacy. Unlike the majority of pills and other oral medications which must be absorbed through the ~~stomach~~digestive ~~directly~~track after being processed through the liver, PuraMed products are placed ~~under the tongue~~ and ~~are~~ absorbed ~~into~~directly ~~the bloodstream through the capillaries~~ under the tongue. Advantages of sublingual dispensing of drugs and medications include faster acting absorption for quick relief, improved efficacy, less stomach upset, and fewer side effects.

PuraMed has secured reliable contract manufacturers to produce and package PuraMed ~~medications~~products in easy-to-use, ~~pre-measured~~ sublingual dispensers. These selected contractors are experienced in the production and packaging of this type of dispenser. PuraMed believes that ~~our~~its benchmark use of sublingual dispensers ~~will~~should distinguish ~~our~~its products favorably in comparison to most competing OTC products now in the marketplace.

Regulation of PuraMed Products

Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval prior to entering the market. They are nonetheless subject to substantial FDA and other federal regulations governing their use, labeling, advertising, manufacturing, and ingredients. PuraMed believes that ~~our~~its current and proposed development, formulation, marketing, and other practices and procedures will comply fully with all governmental regulations applicable to PuraMed products.

Business Structure

PuraMed ~~functions~~intends to function primarily as a research and development, marketing and sales organization. Product manufacturing, packaging, product fulfillment and other operations ~~are~~intend to be outsourced to experienced and reliable third parties through contracts monitored and controlled by PuraMed. PuraMed believes this structure ~~significantly~~hopefully reduces significantly the production costs and manufacturing time related to making the product commercially available.

Product Manufacturing

Production and packaging of PuraMed products ~~are~~intends to be outsourced to various contract manufacturers known by PuraMed’s management from prior substantial business and contract dealings. Due to the business and contacts developed by PuraMed management over the past years with leading contract manufacturers, PuraMed ~~believes~~is convinced it ~~obtains~~can obtain professional and timely production, packaging, and delivery ~~for~~of all PuraMed products.

The Company outsources four main components of ~~our~~the Company’s production process to third-party vendors. The process begins with the sourcing of raw materials, manufacturing of the liquid-gel medicine, testing, and quality assurance of the product itself by Hillestad Pharmaceuticals (http://www.hillestadlabs.com/) in Woodruff, ~~Wisconsin~~WI. Hillestad Pharmaceuticals is an FDA licensed prescription drug manufacturer.

The Company sources all of its packaging needs ofincluding the ~~boxes~~box, box inserts, and 6-pack retail display trays to Proteus Packaging (http://proteuspackaging.com/about-proteus) in Franklin, ~~Wisconsin~~WI.

The final packaging process is completed by the Unette Corporation (http://www.unette.com/index.html) in Randolph, ~~New Jersey~~NJ. This includes the filling of the 3-ml applicator with the liquid-gel medication, the packing of the retail boxes, and the packaging of the master cases.

The Company uses Great Lakes Fulfillment (http://glfulfillment.com) in Lewiston, MAME for all of ~~our~~its ~~eCommerce~~e-commerce and retail distribution needs.

12[14]

Clinical Trials

Conducting clinical trials is a very important component the Company’s marketing plan. With ~~our~~the Company’s goal to get medical professionals to review, endorse, and recommend ~~our~~its product, clinical evidence to support the products’ claims is a prerequisite. The Company has and ~~will~~intends to continue to attend medical trade shows that attract medical ~~professionals~~professions such as doctors, nurses, and pharmacists to present the Company’s clinical research regarding ~~our~~the Company’s MigraPure Advanced Migraine Relief formula, which was clinically tested as LipiGesic® M ~~migraine product~~.

The outcome of ~~our~~the Company’s first clinical study was extremely favorable. After 2 hours post-dose (the clinical trial standard), 64% ~~percent~~ of migraines treated with ~~LipiGesic®~~the MMigraPure formula were reduced to mild or no pain. The study concludes that, “sublingual (under-the-tongue) delivery of feverfew/ginger appears safe and effective as a first-line abortive treatment for a population of migraineurs who frequently experience mild headache prior to the onset of moderate to severe headache. It appears to be well tolerated and has no known contraindications with other acute migraine treatments for migraine.”

As a result of the success and the statistical significance of ~~our~~the Company’s first clinical study, the manuscript was accepted for publication in the July/August 2011 edition of the top -ranked, peer-reviewed, medical journal Headache, The Journal of Head and Face Pain. ~~It has and is expected to continue to provide us with numerous marketing and promotional opportunities that could significantly help with the retail launch of our LipiGesic® M migraine product.~~

The results of ~~the~~these ~~first~~finding ~~clinical trial~~ were ~~subsequently~~also reanalyzed,. ~~and~~The ~~LipiGesic~~consensus M was ~~reported~~that togiven a larger study, the results could have ~~“robust~~produced ~~efficacy”~~even ingreater ~~the~~success. ~~treatment~~The authors of ~~acute~~the ~~migraine~~reanalysis ~~and~~stated ~~migraine~~that ~~associated~~MigraPure ~~symptoms~~(f/k/a LipiGesic M) has a robust efficacy.

~~Our~~The ~~second~~ clinical ~~study~~trial ~~that~~also ~~focuses~~spawned ona ~~LipiGesic~~third ~~M’s~~article ~~efficacy~~published onin Drugs, a medical journal. It was the ~~pediatric~~only ~~and~~OTC ~~adolescent~~medication ~~population~~that iswas ~~nearing~~listed ~~completion~~as an “Advancement” in the treatment of migraine.

~~Children~~The ~~and~~Company ~~adolescents~~expects ~~that~~the ~~suffer~~results ~~with migraines have limited treatment options as many~~ of the ~~traditional~~clinical ~~prescription~~trial ~~remedies~~to ~~have~~provide ~~adverse~~it ~~side effects and are not recommended for use~~ with ~~children~~numerous marketing and ~~adolescents.~~promotional ~~There~~opportunities ~~are an estimated 10 million migraine sufferers~~ that ~~find~~positively ~~themselves~~impact inthe ~~this~~re-launch ~~demographic~~of inMigraPure, ~~the~~Advanced ~~United~~Migraine ~~States~~Relief.

~~There~~The ~~are~~Company’s ~~plans~~second toclinical ~~conduct~~study afocused ~~large~~specifically ~~population~~on ~~study~~children ofand ~~LipiGesic~~adolescents. MThe inpreliminary ~~cooperation~~data ~~with~~from ~~the~~that ~~National~~study ~~Headache~~Suggests ~~Foundation.~~that ~~The~~MigraPure ~~start~~could ~~date~~provide ofan ~~this~~excellent ~~study~~treatment ~~has~~option ~~yet~~for tomany beyoung ~~determined~~sufferers.

There are an estimated 10 million migraine sufferers that find themselves in this demographic in the United States. Children and adolescents that suffer with migraines have limited treatment options as many of the traditional prescription remedies have adverse side effects and are not recommended for use with children and adolescents.

Sales and Marketing

PuraMed intends to concentrate its efforts on ~~its~~the Company’s initial product ~~LipiGesic~~re-launch Mof ~~migraine~~MigraPure ~~headache relief~~ product. ~~When~~ itAfter ~~reaches~~the Company has reached a level of sales that will sustain the product, ~~and~~an additional product offerings, ~~PuraMed~~the ~~will~~ launch of a second product will result. All of the Company’s additional product offerings will follow athe ~~pre~~same three-~~determined~~phase ~~marketing~~process ~~strategy~~to ~~based~~market onas ~~performance and specific milestones.~~MigraPure:

~~PuraMed~~Phase ~~will~~One ~~continue~~Rollout: toDirect ~~use~~Response aand ~~variety~~Sampling. ofThe ~~marketing~~re-entry ~~media~~of toMigraPure ~~increase~~Advanced ~~consumer~~Migraine ~~awareness~~Relief ofinto the ~~LipiGesic~~marketplace Mwill ~~brand.~~commence ~~There~~with ~~has~~direct-response ~~been~~campaigns ~~increased~~to ~~interest~~targeted inmedical ~~e-tailing~~populations; ~~Amazon.com~~distribution through selected retail outlets, ~~the~~natural ~~medical~~products stores and independent pharmacies; a military sampling ~~project,~~program and ~~which~~an ~~had~~internet ~~been~~marketing oncampaign ~~hold~~that ~~during~~includes organic as well as PPC efforts. In addition to the ~~last~~proposed ~~few~~marketing ~~months,~~strategies to build awareness and product purchase, PuraMed is expected to beimplement ~~implemented~~a instrong ~~March~~customer ~~and~~service ~~April~~program ~~2014~~to retain loyal customers.

~~The~~MigraPure’s ~~development~~re-entry ofwill include a ~~new~~re-packaging ~~social~~effort ~~media~~that ~~strategy~~should ~~will~~enhance ~~also~~the ~~increase~~brand’s ~~online~~appeal ~~awareness~~to ~~utilizing~~the ~~several~~public. ~~social~~Other ~~media~~products ~~platforms~~in tothe ~~create~~MigraPure aproduct ~~dialogue~~line ~~with~~are ~~consumers~~planned and underway.

The Company is currently engaging in substantial activities in an attempt to gain broader retail distribution for LipiGesic M through mainstream drug store chains, mass merchandisers, and food chains. We began retail distribution with the nation’s two largest retail chain drug stores, Walgreens and CVS, and we have continued distribution with CVS, but not with Walgreens. However, the Company is continuing our negotiations with other national retail chains in an effort to broaden our retail distribution. The Company hopes expand the retail placement of our migraine product in an additional 21,000 targeted retail outlets including mass merchandisers such as Wal-Mart and Target, food store chains such as SuperValu, Kroger and Safeway, and additional well-known regional drugstores. These retailers were targeted according to various material criteria, including cost of entry, geography, demographics and consumer preference.[15]

~~The~~When ~~Company~~the isMigraPure ~~currently~~Advanced ~~undertaking~~Migraine ~~substantial~~Relief ~~activities~~shows insustained angrowth, ~~attempt~~we plan to ~~gain~~develop ~~broader~~additional ~~retail~~marketing ~~distribution~~assets ~~for~~promotion ~~LipiGesic®~~of Mthe ~~through~~product ~~international~~in ~~distributors,~~other astargeted ~~well~~medical markets and selected retail venues.

~~PuraMed~~Phase ~~will~~Two ~~continue~~Rollout: ~~its~~Retail ~~efforts~~Drugstores. toUpon ~~gain awareness in~~ the ~~medical~~successful ~~community~~completion ~~through efforts~~of ~~through~~the ~~direct~~Phase ~~marketing~~One ~~efforts targeted at medical professionals including physicians~~Rollout, ~~pharmacists,~~PuraMed ~~nurse~~plans ~~practitioners~~to ~~and~~begin ~~physician~~the ~~assistants.~~process ~~This~~of ~~may~~working ~~also~~closely ~~include~~with ~~attendance~~major atdrug ~~medical~~chains ~~conferences~~to ~~attended~~sell byMigraPure ~~Company~~Advance ~~representatives.~~Migraine ~~Venues~~Relief ~~may~~in ~~include~~stores ~~Diamond~~across ~~Headache~~the ~~Conference,~~nation ~~American~~with ~~College~~the ofgoal ~~Physicians, National Conference~~ of ~~Nurse~~self-sustainability ~~Practitioners, the AphA Pharmacy conference,~~ and ~~others~~revenue generation.

13Phase Three Rollout: Further Retail Outlets. A few months after completing the phase two rollout for its migraine remedy, PuraMed plans to launch phase three which will consist of working to expand the retail placement of its migraine product in approximately an additional 21,000 targeted retail outlets including mass merchandisers such as Wal-Mart and Target, food store chains such as SuperValu, Kroger and Safeway, and additional well-known regional drugstores.

~~The~~PuraMed ~~Company~~has ~~will~~selected ~~continue to~~these ~~utilize~~targeted ~~medical~~retailers ~~spokespersons~~according to ~~promote~~various ~~our~~material ~~LipiGesic® M product as they are available. They include Dr. Roger Cady~~criteria, ~~who~~including iscost ~~the founder~~ of ~~Headache Care Center~~entry, ~~Clinvest and Primary Care Education Network; and Dr. Jerome Goldstein~~geography, ~~who~~demographics ~~is a board certified medical neurologist with a special interest in the diagnosis, treatment, prevention,~~ and ~~cure~~consumer ~~of headache~~preference.

~~The~~After ~~Company’s two-count,~~achieving ~~fold-over,~~material ~~sample~~initial ~~pack~~distribution ~~sufficient~~for PuraMed products, PuraMed plans to ~~treat~~initiate ~~one~~a ~~migraine~~comprehensive ~~headache,~~and ~~will~~ongoing bepromotional acampaign ~~key~~directed ~~component~~toward consumer groups it has identified from its product rollouts. The objective of ~~the~~its ~~direct-mail~~promotional campaign is to ~~healthcare~~build ~~providers,~~consumer ~~who~~awareness ~~specialize~~and indevelop ~~the~~a ~~treatment~~consumer-based ofdemand ~~migraine.~~for ~~This~~MigraPure ~~program~~throughout ~~will~~the ~~target~~United ~~headache~~States. ~~specialists,~~The ~~primary~~scope ~~care~~of ~~practitioners,~~the ~~veterans,~~Company’s ~~and~~brand ~~interested~~building ~~consumers~~effort ~~from~~is ~~our~~expected ~~social~~to ~~marketing~~span ~~and~~all ~~eCommerce~~of ~~efforts.~~the following major advertising venues:

~~During~~Trade ~~the~~Advertising ~~last~~– 12Consisting ~~months~~of retail POS (point-of-sale) materials, ~~PuraMed’s~~coupon ~~LipiGesic~~redemption ~~product~~programs, ~~was~~in-store ~~featured~~promotional onvideo, ~~the~~pharmaceutical ~~Big~~trade ~~Biz~~magazines ~~Show~~like ~~several~~Pharmacy ~~times.~~Times, ~~These~~and ~~appearances~~Mass ~~led~~Market toRetailer, key primary care and medical journals, articles in consumer-focused magazines like Headwise a ~~guest~~publication ~~appearance~~of onthe ~~Armed~~National ~~Forces~~Headache ~~Radio.~~Foundation, ~~The~~2015 ~~leadership~~attendance at the NACDS (National Association of ~~PuraMed~~Chain ~~will~~Drug ~~continue~~Stores) toTrade ~~pursue~~Show and ~~take~~other ~~advantage~~industry ofevents. ~~these~~In ~~opportunities~~addition, MigraPure, is expected to be featured in several key primary care and medical journals.

~~One~~Medical ~~study~~Conferences ~~indicates~~and ~~that~~Meetings ~~soldiers~~– ~~were~~A ~~shown~~key tocomponent ~~have~~of ~~two to four times~~ the ~~incidence~~marketing ~~rate~~effort ofwill ~~migraine~~be asdirected ~~compared~~at toeducating ~~the~~medical ~~general~~professionals ~~population. In~~including ~~response~~physicians, topharmacists, ~~this~~clinicians, ~~the~~practitioners, ~~Company~~nurse ~~has~~practitioners ~~been~~ and ~~continues~~physician ~~to provide veterans and members of the armed forces with a free sample of LipiGesic M~~assistants. ~~LipiGesic M is among the top four items requested in the America Cares Project care packages that are delivered by Honor Our Troops to US military personnel serving in Afghanistan.~~

~~The~~Medical ~~company~~Spokespersons ~~will~~– ~~continue~~The toCompany ~~develop~~is ~~relationships~~working ~~for it Business-~~to~~-Business~~ ~~program.~~identify ~~American~~and ~~businesses~~utilize ~~lose~~medical ~~millions~~spokespersons ~~of dollars each year, due~~ to ~~migraines,~~promote ~~which~~MigraPure ~~lead~~Advanced toMigraine ~~employee~~Relief. ~~absenteeism~~They orwill ~~diminished~~include ~~performance.~~board ~~The~~certified ~~Company~~specialists iswith ~~initiating~~ a ~~business-to-business~~special ~~program~~interest toin ~~show~~the ~~other~~diagnosis, ~~companies~~treatment, ~~how~~prevention ~~they~~and ~~can~~cure ~~save~~of ~~money by decreasing lost production hours~~headache.

~~Web~~Consumer ~~Presence~~Advertising ~~and~~– ~~Social~~PMBS ~~Marketing~~plans ~~will~~to beallocate ~~aggressively~~monies ~~implemented.~~to ~~The~~create ~~Company~~media ~~currently~~assets ~~maintains~~that acan ~~corporate~~be ~~website~~leveraged aton ~~www.puramedbioscience.com~~several ~~and~~media avenues ~~product~~and ~~website~~used atin ~~www~~several markets.~~lipigesic.com.~~ ~~Our~~This ~~product~~may ~~website~~include ~~has~~video, ~~gone~~print ~~through~~and aelectronic ~~substantial~~advertising ~~renovation~~that ~~and~~will ~~includes~~be ascheduled ~~blog,~~based ~~sampling~~on ~~program,~~selected ~~promotional~~marketing ~~media~~criteria, goals and ~~testimonial page~~funding.

~~Social~~Product ~~media~~Sampling ~~marketing~~– ~~utilizing~~The ~~Facebook~~Company ~~and~~has ~~Twitter~~developed isa ~~projected~~retail tobox ~~increase~~and ~~during~~a ~~the~~two-count, ~~second~~fold-over, ~~quarter~~sample ofpack ~~2014.~~sufficient ~~In addition~~ to ~~providing~~treat ~~product~~one ~~information,~~migraine ~~this~~headache. ~~program~~These isitems ~~designed~~are asused ~~a tool~~ to ~~direct~~provide ~~consumers~~samples to ~~retail~~headache ~~locations~~specialists, ~~and~~primary ~~special~~care ~~promotions.~~practitioners, ~~In addition to social media campaigns~~veterans, ~~PuraMed~~and ~~plans~~interested toconsumers ~~create~~from ~~e-newsletters~~its ~~for~~social ~~consumers~~marketing and ~~investors~~eCommerce ~~during the second quarter of 2014~~efforts.

Special Programs – The Company has implemented a special program for active-duty servicemen and women and returning Veterans. The Company is currently working with Honoring Our Troops, Operation Gratitude, and Operation Troop Aid to distribute its current product, MigraPure.

Studies show that veterans returning from active duty combat zones experience migraines more often than civilians. One study indicates that soldiers have two to four times the incidence of migraine than the general population. Returning veterans are also at greater risk of suffering from post-traumatic stress disorder (PTSD). Since commonly prescribed medications for PTSD are not compatible with the prescription medications normally used for migraine, these veterans are forced to choose to treat one condition or the other.

MigraPure has no known or reported drug interactions of this type, making it a safer choice for veterans suffering with migraine and PTSD.

[16]

In response to this, the Company has been and plans to continue providing veterans and members of the armed forces with a free sample of MigraPure. MigraPure is among the top four items requested in the America Cares Project care packages that were delivered by Honoring Our Troops to US military personnel serving in Afghanistan.

Web Presence and Social Marketing – The Company currently maintains a corporate website at www.puramedbioscience.com and a product website at www.lipigesic.com, which will transition to www.migrapure.com at the time of the re-launch. The Company plans to maintain the lipigesic.com and other URLs, but redirect visitors to a landing page declaring the change and funnel them to the informational pages and ecommerce site.

E-mail campaigns to targeted audience to promote MigraPure are planned for implementation during the second quarter of 2015.

The Company plans to hire a dedicated social media content manager to direct and implement an active social marketing campaign utilizing Facebook and Twitter and eventually other social media platforms. In addition to providing product information, this program is designed as a tool to direct consumers to retail locations and special promotions.

Competition

The non-prescription healthcare market in which PuraMed is engaged is intensely competitive. and PuraMed ~~faces~~will face the same challenges as other start-up and established OTC drug companies within their respective product classes. Virtually all direct competitors to the PuraMed product line have substantially greater financial, personnel, development, marketing, and other resources than those possessed by PuraMed, which places PuraMed at a definite competitive disadvantage. Main competitors of PuraMed will have substantially larger sales volumes than PuraMed expects to realize, and also greater business diversification in most cases.

PuraMed also must compete with numerous small companies selling products into the same mainstream marketing channels targeted by PuraMed. PuraMed also expects to encounter additional competitors emerging from time to time.

PuraMed believes that the principal competitive factors in its industry include quality and pricing of products, product effectiveness, customer preferences, brand awareness, and marketing and distribution networks. There is no assurance PuraMed will be able to compete successfully against current or future competitors or that the competitive pressures faced by PuraMed will not harm its business materially.

Intellectual Property

PuraMed owns and asserts proprietary intellectual property rights regarding its various products, including a patent, trademarks, formulation technology, ingredients, and ~~drug~~product delivery procedures or methods. The future growth and success of the Company will depend in large part upon its ability to protect its trademarks, trade names and trade secrets. In addition to applying for certain product patents, PuraMed will rely upon trade secrets, proprietary know-how, and continuing development and innovation to compete in its OTC marketplace. Although no claims or threats of product or patent infringement have arisen regarding PuraMed or its products, there is no assurance PuraMed will be able to protect its intellectual property effectively, and any failure to do so would be harmful to PuraMed.

On January 2, 2013 the United States Patent Office granted a patent allowance for the PuraMed BioScience patent application number 12/144,391 entitled “Compositions and Methods for Treating and Preventing Migrainous Headaches and Associated Symptoms”. This non-provisional patent was applied for on June 23, 2008 and will provide patent protection until June 23, 2028.[17]

We believe the granting of the patent for our lead product LipiGesic M is a major milestone achievement and adds considerable value to the intellectual property portfolio of the Company. We believe this patent allowance also gives further evidence of the Company’s ability to create and develop unique products that are useful for helping millions of people suffering from difficult medical conditions.

Future Health and Wellness Opportunities

In its mission to be primarily a research, development, marketing, and sales organization, PuraMed has been building relationships with companies to access other health and wellness products and technologies. These products and technologies address national and international needs and will expand the Company’s product offerings. PuraMed plans to distribute these products globally through strategic partnerships, manufacturing alliances, and national and international licensing and branding agreements.

These state-of-the-art technologies provide needed solutions to combat infection, provide effective and affordable pain relief, fight glaucoma, and improve appearance and brain function. These products utilize leading-edge formulations, delivery systems, and naturally derived active ingredients, for use in medical applications for both the human population and animals.

Due to PuraMed’s management having extensive and working relationships within the scientific and pharmaceutical communities, the Company believes it has the ability to produce and distribute these additional product lines to consumers through retail, direct–response, online, and wholesale distribution channels as is appropriate to the unique markets they serve.

Employees and Facilities

As of ~~February~~November 184, 2014, PuraMed has three employees including its two executive officers, and an office manager. PuraMed anticipates hiring one or more experienced sales and marketing personnel to support the upcoming commercial ~~launches~~launch of ~~its~~MigraPure ~~initial~~within ~~products~~the next 12 months.

Corporate Contact Data

The address of the Company in suburban Wausau, Wisconsin, is 1326 Schofield Avenue, P.O. Box 677, Schofield, WI 54476; ~~our~~the Companys’ telephone number is (715) 359-6373 and ~~our~~the Company’s corporate and product website addresses are www.puramedbioscience.com and www.lipigesic.com, respectively.

Results of Operations

Revenues

Revenues consist of wholesale and website sales of the ~~LipiGesic®~~MigraPure M migraine product. The wholesale revenue is reduced by coop advertising costs incurred to obtain product placement at large retail drugstores.

Cost of Sales

Cost of sales consists of merchant fees, material, packaging, freight costs and product placement expenses that exceed revenue for the units sold.

Operating Expenses

Selling, general and administrative expenses consist primarily of payroll taxes, health insurance, facility rent and administrative overhead costs.

Amortization and depreciation expenses consist primarily of depreciation of assets and amortization of ~~our~~the Company’s LipiGesic® trademark and intellectual property received during ~~our~~its spin-off from ~~our~~the parent company in April 2007.

Marketing and advertising expense include payments for public relations, stock promotion and advertising consistent with the commercialization of products.

Professional fees consist of audit, legal, transfer agent, consulting, commission and directors fees.

Salaries include payments to ~~our~~the office manager.

Officers’ salaries include payroll to ~~our~~the Chief Executive Officer, ~~Chief Operating Officer~~ and ~~our~~ Chief ~~Financial~~Operating Officer.

Other Income Expense

Other Income Expense consists of interest expense and gain/loss on derivative liability.

Comparison of Operations for Three Months Ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013

Revenue

Net revenue for the three months ended ~~December~~September 3130, ~~2013~~2014 ~~and~~was ~~2012~~$3,636 ~~was~~compared to $0 for the three months ended September 30, 2013. The revenue increased due to internet sales.

[18]

Cost of Sales

Cost of sales for the three months ended ~~December~~September 313, ~~2013~~2014 was $~~386~~4,~~013~~932, compared to $1526,~~024~~603 for the three months ended ~~December~~September 3130, ~~2012~~2013. ~~The~~Cost ~~cost~~ of sales ~~increased~~decreased ~~mainly~~ due to ~~1) allowing for obsolete finished goods inventory in~~ the ~~amount~~absence of ~~$166,415,~~obsolete ~~and 2) a customer informed the company that product in the amount of $212,019 was defective due to required packaging changes. The Company therefore wrote off the defective~~ inventory~~. The~~ ~~finished~~write ~~goods inventory allowance was recorded because of decreased sales and inventory turnover~~offs. ~~receiving retail product returns that were damaged, which product was written off in the amount of $212,019.~~

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $5423,~~427~~774 and $5043,~~557~~226 for the three months ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013, respectively. The ~~increase~~decrease is primarily attributed to ~~bad debt expense of $20,511 and $0 during~~ the ~~three~~decrease ~~months~~in ~~ended~~cost ~~December~~of ~~31,~~our ~~2013~~product ~~and~~liability ~~2012, respectively, which was partially offset by decreased~~ insurance ~~expenses~~policy.

Amortization and Depreciation

Amortization and depreciation expenses for the three months ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013 were ~~similar at~~ $143,~~472~~513 compared to $1214,~~975~~440, respectively. The decrease was due to certain intangible assets becoming fully amortized in 2014.

Professional Fees

Professional fees for the three months ended ~~December~~September 3130, ~~2013~~2014 were $5148,~~875~~897 compared to $~~110~~107,~~165~~930 for the three months ended ~~December~~September 3130, ~~2012~~2013. The decrease was attributed to the reduction in ~~payments~~legal tofees ~~consultants~~incurred.

Marketing and Advertising Expense

Marketing and advertising expense for the three months ended ~~December~~September 3130, ~~2013~~2014 was $569,~~857~~770 compared to $6822,~~827~~900 for the three months ended ~~December~~September 3130, ~~2012~~2013. The decrease in the expenses was due to a reduction in the marketing and advertising expenditures.

Research and Development Expenses

Research and development expenses were similar for the three months ended December 31, 2013 was $0 compared $56 for the three months ended December 31, 2012.

Salaries

Salaries for the three months ended ~~December~~September 3130, ~~2013~~2014 were $65,~~996~~874, ~~relatively~~compared ~~unchanged~~to ~~from~~ $7,~~040~~436 for the three months ended ~~December~~September 3130, ~~2012~~2013. The decrease was due to the decrease in hours worked by the Office Manager during this time period.

Officers’ Salaries

Officers’ salaries for the three months ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013 were $6042,~~923~~314 and $9060,~~462~~923, respectively. The decrease in salaries is attributed to the resignation of the Company’s Chief ~~Financial~~Operating Officer onin May 15of 2014, ~~2013~~and a decrease in hours worked by the new Chief Operating Officer.

Interest Expense

Interest expense ~~increased~~for ~~to $170,174 during~~ the three months ended ~~December~~September 3130, 2014 and 2013 ~~from~~was $~~146~~431,~~316~~930 ~~for~~and ~~the~~$125,999, ~~three~~respectively. ~~months~~The ~~ended~~increase ~~December~~in ~~31,~~the ~~2012.~~expense ~~This~~is ~~increase~~attributed ~~was~~to ~~caused~~an ~~primarily~~increase byin the ~~increase~~number inof notes ~~payable~~ outstanding.

~~Gain (~~Loss) on Derivative Liability

The loss on derivative liability for the three months ended ~~December~~September 3130, 2014 and 2013 was $~~108~~255,~~608~~281 and ~~the gain on derivative liability for the three months ended December 31, 2012 was~~ $~~182~~293,~~062~~171, respectively. The loss ~~or gain~~ on derivative liability is the difference in value using the lattice model for the warrants between the date issued and the quarter ended ~~December~~September 3130, ~~2013~~2014 and ~~2012~~2013.

Net Loss

Net loss for the three months ended ~~December~~September 3130, ~~2013~~2014 was $~~910~~822,~~345~~649 compared to $~~319~~702,~~360~~718 for the three months ended ~~December~~September 3130, ~~2012~~2013. The increase in the loss for ~~2013~~2014 was due primarily to ~~reserving~~higher ~~for~~interest ~~finished~~costs ~~goods~~associated ~~inventory,~~with ~~expensing~~convertible ~~defective inventory due to required packaging changes and a lack of revenue~~debt.

~~Comparison of Operations for Six Months Ended December 31, 2013 and 2012~~[19]

Revenue

Net revenue for the six months ended December 31, 2013 was $0 compared to $27,534 for the six months ended December 31, 2012. The decrease is due to a reduction in retail orders.

Cost of Sales

Cost of sales for the six months ended December 31, 2013 was $412,616 compared to $28,067 for the six months ended December 31, 2012. The cost of sales increased mainly due to 1) allowing for obsolete finished goods inventory in the amount of $166,415, and 2) a customer informed the company that product in the amount of $212,019 was defective due to required packaging changes. The Company therefore wrote off the defective inventory. The finished goods inventory allowance was recorded because of decreased sales and inventory turnover. receiving retail product returns that were damaged, which product was written off in the amount of $212,019.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $97,653 and $106,108 for the six months ended December 31, 2013 and 2012, respectively. The decrease is primarily attributed to the decrease in cost of our insurance expenses, which was partially offset by an increase in bad debt expense.

Amortization and Depreciation

Amortization and depreciation expenses for the six months ended December 31, 2013 and 2012 were similar at $28,912 compared to $25,951 respectively.

Professional Fees

Professional fees for the six months ended December 31, 2013 were $159,805 compared to $270,494 for the six months ended December 31, 2012. The decrease was attributed to the reduction in consulting and legal fees incurred.

Marketing and Advertising Expense

Marketing and advertising expense for the six months ended December 31, 2013 was $79,847 compared to $316,338 for the six months ended December 31, 2012. The decrease in the expenses was due to a reduction in the marketing and advertising expenditures.

Research and Development Expenses

Research and development expenses for the six months ended December 31, 2013 was $0 compared to $14,656 for the six months ended December 31, 2012. The decrease is due to the fact that we did not incur any R&D expenses in the six months ended December 31, 2013.

Salaries

Salaries for the six months ended December 31, 2013 were $14,432, relatively unchanged from $14,300 for the six months ended December 31, 2012.

Officers’ Salaries

Officers’ salaries for the six months ended December 31, 2013 and 2012 were $121,846 and $167,820, respectively. The decrease in salaries is attributed to the resignation of the Company’s Chief Financial Officer on May 15, 2013.

Interest Expense

Interest expense for the six months ended December 31, 2013 and 2012 was $296,173 and $295,649, respectively. The interest expense is comprised of interest accrued for outstanding debt instruments as well as the amortization of debt discounts for notes used to finance the Company.

Gain (Loss) on Derivative Liability

The loss on derivative liability for the six months ended December 31, 2013 was $401,779 and the gain on derivative liability for the six months ended December 31, 2012 was $111,825. The loss or gain on derivative liability is the difference in value using the lattice model for the warrants between the date issued and the six months ended December 31, 2013 and 2012.

Net Loss

Net loss for the six months ended December 31, 2013 was $1,613,063 compared to $1,100,024 for the six months ended December 31, 2012. The increase in the loss for 2013 was due primarily to reserving for finished goods inventory, expensing defective inventory due to required packaging changes and a lack of revenue.

Financial Condition, Liquidity and Capital Resources

As of ~~December~~September 3130, ~~2013~~2014, the Company had cash of $028,120 and negative working capital of $45,~~296~~628,~~215~~766.

18PuraMed intends to raise the funds needed to implement the Company’s plan of operation through both private sales of debt and equity securities. There is no assurance, however, that the Company will be successful in raising the necessary capital to implement the Company’s business plan, either through debt or equity sources.

We intend to raise the funds needed to implement our plan of operation through both private sales of debt and equity securities. There is no assurance, however, that we will be successful in raising the necessary capital to implement our business plan, either through debt or equity sources.

Business Strategy

PuraMed’s business strategy going forward is to ~~advertise~~re-launch ~~and promote of~~ its flagship migraine product LipiGesic® M using the name and branded image MigraPure®. The Company plans to begin the promotion of MigraPure with a strong online presence and sampling program that will build awareness and acceptance of the general population and in ~~order~~selected markets. The goal of the re-launch is to drive sales atin ~~our~~both ~~retail~~the ~~drug~~online ~~chains~~marketplace and in selected markets and to generate revenue. PuraMed’s primary goal is to achieve continual material growth of ~~LipiGesic~~MigraPure® migraine product sales through ~~mainstream~~online ~~drug,~~and ~~mass merchandiser~~ brick-and-mortar ~~food~~natural ~~retail~~drug distribution channels, while at the same time promoting ~~LipiGesic~~MigraPure® brand awareness to realize substantial profitability as soon as possible. To implement this strategy, PuraMed intends to execute the following activities during the next twelve months:

The ~~Successful~~Publication ~~Outcome~~ of the Clinical Trial -Data ~~The~~– We believe the outcome of ~~our~~the Company’s 2011 clinical study coupled with the publication of the manuscript in the peer reviewed-medical journal “Headache, The Journal of Head and Face Pain” has proved to be very successful. It has and is expected to continue to provide usit with numerous marketing and promotion opportunities that could significantly help with the ~~retail~~ re-launch of ~~our~~its ~~LipiGesic®~~MigraPure M migraine product. PuraMed is in the process of executing a detailed marketing plan that focuses on the medical community since the successful outcome of our clinical study trial supports such actions. The plan will include renewed detailing, mailings and samples along with internet efforts once all of the funding obtained. The study, re-analysis and the Drugs article are all available on our website. Medical marketing efforts geared toward doctors, physician’s assistants, pharmacists, etc. is expected to be very lucrative as a component in our overall marketing strategy. Our second clinical study that focuses specifically on children and adolescents is currently in process. There are an estimated 10 million migraine sufferers that find themselves in this demographic in the United States. Children and adolescents that suffer with migraines have limited treatment options as many of the traditional prescription remedies have adverse side effects and are not recommended for use with children and adolescents. The successful outcome of this clinical trial will also enhance this effort.

~~Commercialize~~ PuraMed ~~Products~~is –in ~~In addition to raising~~ the ~~necessary~~process ~~funds to continue operations, PuraMed’s primary focus for the remainder~~ of ~~calendar~~creating ~~year~~a ~~2014~~detailed ~~will~~marketing bestrategy tothat ~~gain~~focuses ~~distribution~~on ~~with~~the ~~one~~sampling orand ~~more~~engagement ~~additional~~of ~~national~~segments ~~chain~~of ~~drug stores. In addition,~~ the ~~Company~~medical ~~will~~community. beThe ~~implementing a marketing campaign utilizing its~~ successful ~~clinical~~outcome ~~study. The~~and ~~Company~~subsequent ~~has~~re-analysis ~~begun the execution~~ of ~~our~~MigraPures ~~marketing~~clinical ~~campaign~~trial ~~utilizing~~data ~~our~~is ~~Clinical~~expected ~~Trials~~ to ~~overcome~~be ~~consumer~~an ~~and~~instrumental ~~retailer~~component ~~skepticism and provide third party validation~~ of ~~our~~those ~~migraine products efficacy~~actions. ~~The~~Medical ~~Company’s~~ marketing efforts ~~will~~targeting ~~have~~specific asegments ~~strong~~of ~~consumer~~the ~~emphasis~~medical ~~including a Social Marketing campaign, medial~~ community ~~detailing~~are ~~and~~expected sampling, Continuing Medical Education (CME) program for doctors and pharmacists, Medical conference participation and Celebrity endorsements. In addition our website and eCommerce efforts will be enhanced to ~~optimize~~yield ~~our~~positive ~~internet sales as a result of our new marketing campaign~~returns. ~~PuraMed also has plans to test direct response radio advertising and upgrade its Social Marketing efforts that include Facebook, Twitter, and YouTube.~~

~~Expansion~~The ofdata ~~Sales~~that ~~and~~the ~~Marketing~~Company ~~Activities~~has –received ~~PuraMed~~regarding ~~will~~its ~~continue~~clinical totrial ~~expand~~focusing ~~upon~~on ~~its~~the ~~marketing~~adolescent ~~activities~~population ~~which~~is ~~have~~expected ~~been~~to ~~focused~~further ~~toward~~underscore ~~obtaining~~the avalidity ~~nationwide network~~ of ~~retail~~feverfew ~~outlets~~ and ~~employing~~ginger ~~“direct~~as toan ~~consumer”~~safe ~~media~~and ~~advertising~~effective formulation for ~~its~~the ~~planned~~treatment ~~product~~of ~~sales,~~migraine asin ~~well~~the asyouth ~~promoting~~ and ~~building~~adolescents. ~~LipiGesic®~~Treatment ~~brand~~options ~~awareness.~~for ~~PuraMed~~this ~~will~~demographic, ~~participate~~conservatively inestimated ~~industry~~at ~~trade~~10 ~~shows~~million ~~and~~are ~~similar~~limited. ~~events,~~The ~~and~~traditional ~~also~~prescription ~~will~~migraine ~~engage~~remedies inhave ~~substantial~~adverse ~~media~~side ~~advertising~~effects and ~~direct~~are ~~sales~~not ~~media~~recommended ~~campaigns~~for touse ~~attract~~by children and ~~secure consumers for PuraMed products~~adolescents.

~~Continuation~~Commercialization ofPuraMed ~~Product~~Products ~~Development~~ – ~~Besides~~In ~~its~~addition ~~already~~to ~~developed~~raising ~~products~~the necessary funds to continue operations, PuraMed’s ~~will~~primary ~~complete~~focus ~~development~~for the remainder of calendar year 2014 and ~~testing~~beginning of ~~additional~~2015 ~~non~~is expected to be to continue the re-~~prescription~~branding ~~drugs~~process and ~~nutritional~~gain ~~supplements~~distribution with one or more retail channels. The Company will work to beuse ~~commercially~~its ~~launched~~clinical indata, ~~the~~anecdotal ~~future~~information asand ~~additional~~an ~~LipiGesic®~~aggressive sampling campaign to overcome consumer and retailer skepticism, provide third-party validation of its migraine products efficacy and achieve retail and online placement.

19The Company’s also plans to implement a strong online marketing campaign that expects to drive organic traffic to either The Company’s online store or retail venues after the re-branding of MigraPure is complete. A three-pronged marketing strategy expects to be implemented that targets, consumers, the medication community and retailers. Each target should have marketing plans designed specifically for them to maximize awareness, encourage engagement and prompt purchase. As part of the re-launch efforts an enhanced website, electronic media campaigns and eCommerce portal is expected to optimize its internet sales.

Assuming the Company raises the capital, we anticipate spending approximately $3,000,000 million over the next twelve months on the marketing of our migraine headache remedy along with the introduction of our second product offering regardless of any amounts of revenues we generate from product sales during this period. These funds will be spent as follows:[20]

Expansion of Sales and Marketing Activities – PuraMed plans to continue working to expand and develop marketing strategies focused on gaining a network of retail outlets; implementing direct-to-consumer marketing messages; exhibiting and attending tradeshows of targeted industries, and maintaining a sampling program to build awareness and secure consumers of MigraPure.

Continuation of Product Development – Besides its MigraPure product, PuraMed will work to complete development and testing of its hemp-based product line of non-prescription drugs and nutritional supplements to be commercially launched in the future as additional PuraMed products.

Assuming the Company raises the necessary capital, it anticipates spending approximately $3.0 million over the next twelve months on the marketing of its migraine headache remedy along with the introduction of its hemp-based cannabinoid product offerings regardless of any amounts of revenues the Company generates from product sales during this period. If raised, these funds will be spent as follows:

Sales and marketing expenses	$	2,000,000
Purchase of product inventory, packaging and raw materials		600,000
Research and development activities		100,000
General and administrative expenses including rent, fixed overhead and management compensation		300,000
	$	3,000,000

Critical Accounting Policies

The discussion in this Plan of Operation should be considered in conjunction with ~~our~~the Company’s audited financial statements and related notes included in ~~our~~its Annual Report on Form 10-K for the year ended June 30, ~~2013~~2014, filed with the SEC on October 1514, ~~2013~~2014. These financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (US GAAP).

The preparation of ~~our~~the Company’s financial statements requires us to make estimates and judgments affecting ~~our~~its reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, wePuraMed ~~will~~is expecting to evaluate these estimates which are based on historical experience and certain assumptions wethe ~~believe~~Company believes to be reasonable under the circumstances. Actual results may differ materially from ~~our~~the Company’s estimates under different assumptions or conditions.

~~Product~~Impairment ~~Amortization:~~ – ~~PuraMed®~~Whenever ~~BioScience~~events ~~products~~or ~~consist~~changes ~~primarily~~in ofcircumstances indicate that the ~~cost~~carrying ofamounts ~~trade~~may ~~secrets,~~not ~~formulas~~be recoverable, ~~scientific~~The ~~and~~Company ~~manufacturing~~conducts ~~know-how,~~an ~~trade~~impairment ~~names,~~analysis ~~marketing~~of any material ~~and~~intangible ~~other~~assets ~~intellectual~~owned ~~property~~by ~~and~~the ~~are~~Company. ~~amortized~~If onthe aresults ~~straight-line~~of ~~basis~~any ~~over~~such animpairment ~~estimated~~analysis ~~useful~~indicate ~~life~~the ofCompany’s ~~seven~~recorded ~~years.~~values ~~Amortization~~for ~~expense~~any issuch ~~expected~~assets tohave bedeclined ~~$37~~materially,~~614~~ ~~for~~PuraMed ~~fiscal~~plans ~~year~~to ~~ending~~adjust ~~June~~its recorded asset valuations in all of its financial statements to reflect any such decline in value. The Company believes that no impairment existed as of September 30, 2014.

~~Impairment~~Stock-Based Compensation – ~~Whenever~~PuraMed ~~events~~has orissued ~~changes~~stock-based incompensation ~~circumstances~~to ~~indicate~~the ~~that~~Company’s ~~the~~employees, ~~carrying~~contractors, ~~amounts~~consultants ~~may~~or ~~not~~others beproviding ~~recoverable,~~goods weand ~~conduct~~services anto ~~impairment~~PuraMed. ~~analysis~~The fair market value of any ~~material~~stock-based ~~intangible~~compensation ~~assets~~issued ~~owned~~for bygoods ~~us.~~or Ifservices is expected to be expensed over the ~~results~~period ofin ~~any~~which ~~such~~the ~~impairment~~Company ~~analysis~~receives ~~indicate~~them. ~~our~~Most ~~recorded~~likely ~~values~~any equity securities issued by it for ~~any~~goods ~~such~~and ~~assets~~services ~~have~~should ~~declined~~consist ~~materially~~of common shares or common stock purchase warrants, wewhich ~~will~~should ~~adjust~~be ~~our~~fully ~~recorded~~vested, ~~asset~~non-forfeitable, ~~valuations~~and infully ~~all~~paid ofor ~~our~~exercisable ~~financial~~at ~~statements~~the todate ~~reflect~~of grant. Regarding any ~~such~~future ~~decline~~stock inoption ~~value.~~or ~~The~~warrant grants, the Company ~~believes~~intends ~~that~~to nodetermine ~~impairment~~the ~~existed~~fair asvalue ofby ~~December~~using ~~31,~~the ~~2013~~Black-Scholes option-pricing model.

Stock-Based Compensation – We have issued stock-based compensation to our employees, contractors, consultants or others providing goods and services to us. The fair market value of any stock-based compensation issued for goods or services will be expensed over the period in which we receive them. Most likely any equity securities issued by us for goods and services will consist of common shares or common stock purchase warrants, which will be fully vested, non-forfeitable, and fully paid or exercisable at the date of grant. Regarding any future stock option or warrant grants, we intend to determine their fair value by using the Black-Scholes option-pricing model.[21]

Derivative financial instruments – warrants – In accordance with guidance in Accounting Standards Codification (ASC) 815-40-25-1 and ASC 815-40-25-8, the Company has determined the warrants issued during 2011 have net cash settlement provisions that require classification as derivative liabilities rather than permanent equity. In accordance with such accounting rules, derivative instruments are recorded at fair value and marked-to-market each period until they are exercised or expire, with any change in the fair value charged or credited to income each period. Because these warrants do not trade in an active securities market, ~~their~~the fair value was estimated using a binomial option-pricing model.

Derivative financial instruments – conversion options – In accordance with guidance in ASC 815-15, the Company has determined the conversion options of certain short-term convertible notes require classification as derivative liabilities. In accordance with such accounting rules, derivative instruments are recorded at fair value and marked-to-market each period until they are exercised or expire, with any change in the fair value charged or credited to income each period. ~~Their~~The fair value was estimated using a binomial option-pricing model.

20[22]

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As described in the notes to condensed financial statements included in this filing (see Note C), the Company accounts for certain warrants and convertible debt instruments as derivative liabilities. However, wePuraMed dodoes not engage in any hedging activities.

ITEM 4. CONTROLS AND PROCEDURES

The Company’s disclosure controls and procedures are designed to ensure (i) that information required to be disclosed by the Company in the reports in the Company files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms; and (ii) that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive officer, or persons performing similar functions, as appropriate to allow timely decision regarding required disclosure.

Pursuant to rules adopted by the SEC as directed by Section 302 of the Sarbanes-Oxley Act of 2002, the Company’s management, with the participation of the CEO and CFO, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) ) as of ~~December~~September 3130, ~~2013~~2014. Based on that evaluation, the Company’s CEO concluded that, as of that date, the Company’s disclosure controls and procedures required by paragraph (b) of the Exchange Act Rules 13a-15d-15, were not effective. Management’s assessment identified the following material weaknesses:

There is a lack of accounting personnel with the requisite knowledge of US GAAP and the financial reporting requirements of the Securities and Exchange Commission.

There are insufficient written policies and procedures to insure the correct application of accounting and financial reporting with respect to the current requirements of US GAAP and SEC disclosure requirements.

There is a lack of segregation of duties, in that wePuraMed only had one person performing all accounting-related duties.

Notwithstanding the existence of these material weaknesses in ~~our~~the Company’s internal control over financial reporting, ~~our~~ management believes that the financial statements included in its report fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods presented.

The Company also disclosed these weaknesses in ~~our~~its Annual Report on Form 10-K for the year ended June 30, ~~2013~~2014, filed with the SEC on October 1514, ~~2013~~2014. WePuraMed recently added external accountants to assist in ~~our~~the Company’s accounting processes.

21[23]

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS AND RISK FACTORS

There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of ~~our~~its subsidiaries, threatened against or affecting the Company, ~~our~~its common stock, any of ~~our~~its subsidiaries or of the Company’s or ~~our~~its subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

ITEM 1A. RISK FACTORS

WePuraMed ~~believe~~believes there are no changes that constitute material changes from the risk factors previously disclosed in ~~our~~the Company’s Annual Report on Form 10-K for the year ended June 30, ~~2013~~2014, filed with the SEC on October 1514, ~~2013~~2014.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~From~~There ~~July~~were 1,no ~~2012~~unregistered ~~through~~sales ~~June 30, 2013, the Company, through private transactions, offered and sold 430,000 shares~~ of ~~common~~equity ~~stock~~securities toduring ~~four individual investors for a total of $61,350 net of offering expenses. Sale of these common shares was deemed exempt from registration under Section 4(2) of~~ the ~~Securities~~quarter ~~Act~~ended ofSeptember ~~1933~~30, ~~as amended~~2014. No advertising or general solicitation was involved and these shares were offered only to the individual purchasers who are accredited investors. Moreover, the stock certificates for these shares are legended to prevent further transfer, resale or other disposition unless registered under applicable securities laws or exempt from such registration.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

There were no defaults upon senior securities during the quarter ended ~~December~~September 3130, ~~2013~~2014. $652,723 of notes payable are past-due as of September 30, 2014.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

There is no other information required to be disclosed under this item which was not previously disclosed.

22[24]

ITEM 6. EXHIBITS

See Exhibit Index below

Exhibit Index

Quarterly report on Form 10-Q

For the quarter ended ~~December~~September 3130, ~~2013~~2014

31.1*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		Taxonomy Extension Schema Document

101.CAL		Taxonomy Extension Calculation Linkbase Document

101.DEF		Taxonomy Extension Definition Linkbase Document

101.LAB		Taxonomy Extension Label Linkbase Document

101.PRE		Taxonomy Extension Presentation Linkbase Document

*Filed herewith

23[25]

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PURAMED BIOSCIENCE, INC.
Date: February 19, 2014	By:	/s/ Russell W. Mitchell
November 19, 2014	By:	/s/ Russell W. Mitchell
		Russell W. Mitchell
		Chief Executive Officer
		(Principal Executive Officer)
		(Principal Financial Officer)
		(Principal Accounting Officer)

Pursuant to requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name	Title	Date
/s/ Russell W. Mitchell	Chief Executive Officer	~~February~~November 19, 2014
Russell W. Mitchell	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer), Director
/s/ James W. Higgins	Chief Operating Officer, Director	February 19, 2014
/s/ Patricia McMurtrie	Chief Operating Officer, Director	November 19, 2014
James W. Higgins
Patricia McMurtrie
/s/ Charles Phillips	Director	~~February~~November 19, 2014
Charles Phillips

[26]

Filing Compare · Puramed Bioscience Inc.